Terumo Health Outcomes Introduces Medis QFR® 3.0 Software for Coronary Assessment in the U.S.

Medis QFR® 3.0 Software Launch by Terumo Health Outcomes

In a significant advancement for cardiac care, Terumo Health Outcomes (THO), part of Terumo Interventional Systems, announced the release of the Medis QFR® 3.0 software, which has received FDA clearance for use within the United States. This cutting-edge software is designed to enhance the processes of coronary physiology assessment, thereby improving clinical outcomes and hospital workflows.

The introduction of Medis QFR 3.0 is a result of THO’s collaboration with Medis Medical Imaging, following their partnership announced in December 2023. This collaboration is aimed at equipping hospitals with state-of-the-art tools that streamline the workflow in catheterization labs (cath labs) while also prioritizing patient comfort—a vital consideration in modern healthcare.

Ryan Graver, Senior Divisional Vice President at THO, underscored the importance of this development, stating, "Helping hospitals access proven, innovative tools like QFR 3.0 is an important part of our mission. This latest advancement aligns with the goals of many hospitals to enhance cath lab efficiency and support high-quality, patient-centered care. We are proud to offer this cardiology diagnostic solution to our customers."

Advanced Capabilities of QFR 3.0

The Medis QFR 3.0 software boasts several enhanced features that improve its usability and effectiveness. The software has undergone rigorous validation, as evidenced by over 200 peer-reviewed publications and data sources from more than 17,000 patients and 20,000 lesions. Its clinical significance is further highlighted by being recommended by the European Society of Cardiology (ESC) in their guidelines published in 2024.

Dr. Maya Barley, CEO of Medis Medical Imaging, expressed her enthusiasm about the software’s introduction into U.S. hospitals, stating, "We are excited that U.S. hospitals will now have access to QFR 3.0. Our collaboration with Terumo Health Outcomes supports our goal of delivering solutions that simplify workflow while maintaining a strong foundation of clinical accuracy."

This partnership showcases the mutual commitment to expanding access to cardiovascular technologies that can positively affect patient care and hospital efficiency. Ghada Farah, President of Terumo Interventional Systems, echoed this sentiment, emphasizing a shared vision for innovative healthcare solutions.

Seamless Integration with ePRISM

THO offers a comprehensive portfolio of products designed to enhance clinical workflows. The ePRISM platform, which provides predictive insights for clinicians to assess patient risks and optimize treatment strategies, complements the QFR 3.0 software perfectly. Together, these tools empower healthcare professionals to make informed decisions that streamline procedures and improve patient care.

The integration of QFR 3.0 with ePRISM can lead to a significant reduction in hospital costs and patient recovery times by facilitating smoother treatment processes based on accurate assessments.

A Commitment to Innovation

Terumo Health Outcomes is steadfast in its mission to improve healthcare through advanced digital solutions. The ePRISM platform offers clinicians real-time insights, enabling them to adopt data-driven strategies that enhance both patient outcomes and operational efficiency. This innovative approach embodies their commitment to delivering high-quality healthcare solutions and improving overall patient experiences.

Founded over 100 years ago, Terumo has remained at the forefront of medical technology, providing innovative solutions that support various medical practices and procedures. With its global presence in over 160 countries and a focus on quality and accessibility, Terumo continues to strive for excellence in the medical field.

For more information, visit Terumo Health Outcomes and learn more about how Medis QFR 3.0 can transform cardiac care in your healthcare facility.

Conclusion

The launch of Medis QFR 3.0 represents a pivotal advancement for U.S. healthcare, positioning hospitals to leverage cutting-edge technology that enhances patient care and workflow efficiency. As Terumo Health Outcomes continues to innovate and collaborate, the future of cardiac assessment technology looks promising.